Trastuzumab Emtansine (T-DM1): No radiosensitizing effect in vitro on HER2-positive breast cancer cells (study in vitro)

被引：0

作者：

Mignot, Fabien ^{[1
]}

Kirova, Youlia ^{[1
]}

Verrelle, Pierre ^{[1
]}

Teulade-Fichou, Marie-Paule ^{[1
]}

Megnin-Chanet, Frederique ^{[1
]}

机构：

[1] Inst Curie, Paris, France

来源：

CANCER RESEARCH | 2020年 / 80卷 / 04期

关键词：

D O I：

10.1158/1538-7445.SABCS19-P1-18-24

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P1-18-24

引用

下载

页数：2

共 50 条

[31] YES1amplification confers trastuzumab-emtansine (T-DM1) resistance in HER2-positive cancer
Wang, Lei
Wang, Quanren
Xu, Piaopiao
Fu, Li
Li, Yun
Fu, Haoyu
Quan, Haitian
Lou, Liguang
BRITISH JOURNAL OF CANCER, 2020, 123 (06) : 1000 - 1011
[32] Safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive advanced breast cancer: Primary results from the KAMILLA study cohort 1
Montemurro, Filippo
Ellis, Paul
Anton, Antonio
Wuerstlein, Rachel
Delaloge, Suzette
Bonneterre, Jacques
Quenel-Tueux, Nathalie
Linn, Sabine C.
Irahara, Natsumi
Donica, Margarita
Lindegger, Nicolas
Barrios, Carlos H.
EUROPEAN JOURNAL OF CANCER, 2019, 109 : 92 - 102
[33] Risk of radionecrosis in HER2-positive breast cancer with brain metastasis receiving trastuzumab emtansine (T-DM1) and brain stereotactic radiosurgery
Chun, Seok-Joo
Kim, Kyubo
Kim, Yong Bae
Paek, Sun Ha
Lee, Kyung-Hun
Song, Jin-Ho
Jang, Won Il
Kim, Tae Hyun
Salvestrini, Viola
Meattini, Icro
Livi, Lorenzo
Shin, Kyung Hwan
RADIOTHERAPY AND ONCOLOGY, 2024, 199
[34] Liquid biopsy identifies actionable dynamic predictors of resistance to Trastuzumab Emtansine (T-DM1) in advanced HER2-positive breast cancer
Matteo Allegretti
Alessandra Fabi
Elena Giordani
Cristiana Ercolani
Paolo Romania
Cecilia Nisticò
Simona Gasparro
Vittoria Barberi
Maria Ciolina
Edoardo Pescarmona
Diana Giannarelli
Gennaro Ciliberto
Francesco Cognetti
Patrizio Giacomini
Molecular Cancer, 20
[35] Liquid biopsy identifies actionable dynamic predictors of resistance to Trastuzumab Emtansine (T-DM1) in advanced HER2-positive breast cancer
Allegretti, Matteo
Fabi, Alessandra
Giordani, Elena
Ercolani, Cristiana
Romania, Paolo
Nistico, Cecilia
Gasparro, Simona
Barberi, Vittoria
Ciolina, Maria
Pescarmona, Edoardo
Giannarelli, Diana
Ciliberto, Gennaro
Cognetti, Francesco
Giacomini, Patrizio
MOLECULAR CANCER, 2021, 20 (01)
[36] Ado-trastuzumab emtansine (T-DM1) is effective against established HER2-positive breast cancer brain metastases in mice
Askoxylakis, V.
Ferraro, G.
Kodack, D.
Badeaux, M.
Jain, R.
CANCER RESEARCH, 2016, 76
[37] Trastuzumab emtansine for HER2-positive breast cancer
Venkatesan, Priya
LANCET ONCOLOGY, 2016, 17 (12): : E528 - E528
[38] Defective Cyclin B1 Induction in Trastuzumab-emtansine (T-DM1) Acquired Resistance in HER2-positive Breast Cancer
Sabbaghi, Mohammad A.
Gil-Gomez, Gabriel
Guardia, Cristina
Servitja, Sonia
Arpi, Oriol
Garcia-Alonso, Sara
Menendez, Silvia
Arumi-Uria, Montserrat
Serrano, Laia
Salido, Marta
Muntasell, Aura
Martinez-Garcia, Maria
Zazo, Sandra
Chamizo, Cristina
Gonzalez-Alonso, Paula
Madoz-Gurpide, Juan
Eroles, Pilar
Arribas, Joaquin
Tusquets, Ignasi
Lluch, Ana
Pandiella, Atanasio
Rojo, Federico
Rovira, Ana
Albanell, Joan
CLINICAL CANCER RESEARCH, 2017, 23 (22) : 7006 - 7019
[39] Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody–drug conjugate in development for the treatment of HER2-positive cancer
Sandhya Girish
Manish Gupta
Bei Wang
Dan Lu
Ian E. Krop
Charles L. Vogel
Howard A. Burris III
Patricia M. LoRusso
Joo-Hee Yi
Ola Saad
Barbara Tong
Yu-Waye Chu
Scott Holden
Amita Joshi
Cancer Chemotherapy and Pharmacology, 2012, 69 : 1229 - 1240
[40] Enhanced antitumor activity of trastuzumab emtansine (T-DM1) in combination with pertuzumab in a HER2-positive gastric cancer model
Yamashita-Kashima, Yoriko
Shu, Sei
Harada, Naoki
Fujimoto-Ouchi, Kaori
ONCOLOGY REPORTS, 2013, 30 (03) : 1087 - 1093

← 1 2 3 4 5 →